CAS 115436-72-1|Sodium risedronate

Introduction：Basic information about CAS 115436-72-1|Sodium risedronate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Sodium risedronate BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
5. Safety Information
6. Articles32
7. Synonyms

Common Name	Sodium risedronate
CAS Number	115436-72-1	Molecular Weight	305.094
Density	/	Boiling Point	692.3ºC at 760 mmHg
Molecular Formula	C₇H₁₀NNaO₇P₂	Melting Point	252-262°C
MSDS	Chinese	Flash Point	372.5ºC
Symbol	GHS07	Signal Word	Warning

Names

Name	Sodium risedronate
Synonym	More Synonyms

Sodium risedronate BiologicalActivity

Description	Risedronate sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: Risedronate sodium, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate sodium is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy [1].The administration of 20 and 25 mg/kg risedronate sodium for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate sodium, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls [2].Clinical indications: Bone resorption; Male osteoporosis; Osteogenesis imperfecta; Osteoporosis; Pagets bone disease Toxicity: abdominal pain; anxiety, back pain; belching, bladder irritation; bone disorders and pain; bronchitis; bursitis; cataracts; chest pain; colitis; constipation; depression; diarrhea; difficulty breathing
Related Catalog	Signaling Pathways >>Others >>OthersResearch Areas >>Others
References	[1]. Giljevic Z, et al. Treatment of osteoporosis by risedronate-- speed, efficacy and safety. Reumatizam. 2006;53(2):66-71. [2]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31.

Description

Risedronate sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: Risedronate sodium, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate sodium is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy [1].The administration of 20 and 25 mg/kg risedronate sodium for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate sodium, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls [2].Clinical indications: Bone resorption; Male osteoporosis; Osteogenesis imperfecta; Osteoporosis; Pagets bone disease Toxicity: abdominal pain; anxiety, back pain; belching, bladder irritation; bone disorders and pain; bronchitis; bursitis; cataracts; chest pain; colitis; constipation; depression; diarrhea; difficulty breathing

Related Catalog

Signaling Pathways >>Others >>OthersResearch Areas >>Others

References

[1]. Giljevic Z, et al. Treatment of osteoporosis by risedronate-- speed, efficacy and safety. Reumatizam. 2006;53(2):66-71.

[2]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31.

Chemical & Physical Properties

Boiling Point	692.3ºC at 760 mmHg
Melting Point	252-262°C
Molecular Formula	C₇H₁₀NNaO₇P₂
Molecular Weight	305.094
Flash Point	372.5ºC
Exact Mass	304.983032
PSA	170.63000
LogP	0.06380
Vapour Pressure	4.03E-20mmHg at 25°C
InChIKey	DRFDPXKCEWYIAW-UHFFFAOYSA-M
SMILES	O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+]
Storage condition	Store at RT

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: SZ8567500

CHEMICAL NAME :: Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt

CAS REGISTRY NUMBER :: 115436-72-1

LAST UPDATED :: 199504

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C7-H10-N-O7-P2.Na

MOLECULAR WEIGHT :: 305.11

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1800 ug/kg/3D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - iritis

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 341,436,1993

Safety Information

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302 + H312 + H332
Precautionary Statements	P280
Hazard Codes	Xi
RIDADR	NONH for all modes of transport
RTECS	SZ8567500

Articles32

Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.

Arch. Pharm. Res. 37(12) , 1560-9, (2014)

Risedronate is widely used clinically to treat osteoporosis, Paget's disease, hypercalcemia, bone metastasis, and multiple myeloma. However, its oral efficacy is restricted due to its low bioavailabil...

Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.

Biochim. Biophys. Acta 1841(7) , 977-86, (2014)

2,3-Oxidosqualene is an intermediate in cholesterol biosynthesis and 2,3:22,23-dioxidosqualene act as the substrate for an alternative pathway that produces 24(S),25-epoxycholesterol which effects cho...

Risedronate increases osteoblastic differentiation and function through connexin43.

Biochem. Biophys. Res. Commun. 432(1) , 152-6, (2013)

Bisphosphonates are potent antiresorptive drugs which have antifracture efficacy by reducing bone turnover rate and increasing bone mineral density. In addition to inhibiting osteoclast function, bisp...

Synonyms

T6NJ C1XQPQQO&PQQO &&Mono Na salt

Actonel

Natriumhydrogen-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonat

Risedronic acid monosodium salt

sodium hydrogen (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonate

Benet

hydrogène (1-hydroxy-1-phosphono-2-pyridin-3-yléthyl)phosphonate de sodium

Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, sodium salt (1:1)

MFCD01706268

phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, monosodium salt

Sodium risedronate

sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate

P,P'-[1-Hydroxy-2-(3-pyridonyl)ethylidene]bis-phosphonic acid sodium salt

Sodium hydrogen [1-hydroxy-1-phosphono-2-(3-pyridinyl)ethyl]phosphonate

Risedronic acid sodium salt

sodium hydrogen-1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethylphosphonate

[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis(phosphonic acid), sodium salt (1:1)

Optinate

Risedronate sodium

Recommended......